Abstracts Archive - Page 849 of 2607 - ACR Meeting Abstracts

Abstract Number: 0189 • ACR Convergence 2020
Determining the Relationship Between Mycobacterium Avium Subspecies Paratuberculosis Serostatus, Dietary Habits, Medication Regimen, and Joint Pain in Patients with Rheumatoid Arthritis
Chelsea Guan¹, Shazia Majid², Sweta Chalise², Saleh Naser², Robert Sharp² and Shazia Beg³, ¹University of Central Florida, Orlando, FL, ²University of Central Florida, Orlando, ³University of Central Florida College of Medicine, Orlando
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease that primarily affects synovial tissues. While the exact etiology is unknown, it is hypothesized that…
Abstract Number: 0190 • ACR Convergence 2020
Hepatic Steatosis in Rheumatoid Arthritis: Frequency and Disease-Related Contributors
Jun Lee¹, Galina Lagos², Joan Bathon¹ and Jon Giles¹, ¹Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ²Columbia University Vagelos College of Physicians and Surgeons, New York
Background/Purpose: Nonalcoholic fatty liver disease (NAFLD), a spectrum of disorders characterized by the presence of hepatic steatosis, is the most common liver disorder in western…
Abstract Number: 0191 • ACR Convergence 2020
Increased Frequency of Lower Limb Arterial Obstruction in Rheumatoid Arthritis
Ahmed Oglah¹, Ali Hussein², Jose Felix Restrepo³, Carlos Lorenzo³, Agustin Escalante³ and Inmaculada Del Rincon³, ¹University of Texas Health Science Center at San Antonio/ Internal Medicine Residency program, San Antonio, TX, ²University of Texas Health Science Center at San Antonio/ Department of Internal Medicine/ Rheumatology, San Antonio, TX, ³University of Texas Health Science Center at San Antonio/ Department of Medicine/ Rheumatology, San Antonio, TX
Background/Purpose: Despite a high frequency of cardiovascular disease in rheumatoid arthritis (RA), peripheral arterial disease in RA has received little attention. The objective of the…
Abstract Number: 0192 • ACR Convergence 2020
Influence of Inflammatory and Non-inflammatory Rheumatic Disorders on the Clinical and Biological Profile of Adult-onset Diabetes
Jerome Avouac¹, Muriel Elhai², Marine Forien³, Jeremie Sellam⁴, Florent Eymard⁵, Anna Molto⁶, Frederic Banal⁷, Joel Damiano⁸, Philippe Dieude³, Etienne Larger⁹ and Yannick Allanore¹, ¹Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, France, ²Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland., Schlieren, Switzerland, ³Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, Ile-de-France, France, ⁴AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, ⁵APHP Henri Mondor Hospital, Creteil, France, ⁶Rheumatology Department, Cochin Hospital, APHP, Paris, France, Paris, France, ⁷Service de Rhumatologie Hôpital d'instruction des armées Bégin, Saint Mande, France, ⁸Service de Rhumatologie Hôpital Sainte Camille, Bry-Sur-Marne, Ile-de-France, France, ⁹Université de Paris, Service de Diabétologie, Hôpital Cochin, AP-HP.CUP, Paris, Ile-de-France, France
Background/Purpose: To compare the profile of adult-onset diabetes in patients with rheumatoid arthritis (RA) or osteoarthritis (OA), two chronic diseases leading to disability differing by…
Abstract Number: 0193 • ACR Convergence 2020
Patients with Asthma Have a Higher Risk of Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Nipith Charoenngam¹, Ben Ponvilawan¹, Thanitsara Rittiphairoj¹, Surapa Tornsatitkul¹, Phuuwadith Wattanachayakul¹, Pongprueth Rujirachun¹ and Patompong Ungprasert², ¹Mahidol University, Bangkok, Thailand, ²Cleveland Clinic, Cleveland, OH, Cleveland Heights, OH
Background/Purpose: Studies have reported the association between asthma and elevated risk of several chronic diseases, such as inflammatory bowel disease, diabetes mellitus and coronary heart…
Abstract Number: 0194 • ACR Convergence 2020
Depression Symptoms but Not Clinically Diagnosed Depression Predict Mortality in Rheumatoid Arthritis
Jose Felix Restrepo¹, Inmaculada Del Rincon¹ and Agustin Escalante¹, ¹University of Texas Health Science Center at San Antonio/ Department of Medicine/ Rheumatology, San Antonio, TX
Background/Purpose: Depression and depressive symptoms are common but under-recognized in rheumatoid arthritis (RA). Few studies have examined depression symptoms in RA patients compared to clinically…
Abstract Number: 0195 • ACR Convergence 2020
Epidemiology and Characteristics of Incident Rheumatoid Arthritis in Persons with and Without HIV
Jennifer Hanberg¹, Kathleen Akgun², Liana Fraenkel³, Evelyn Hsieh² and Amy Justice⁴, ¹Yale University School of Medicine; West Haven VA, Boston, MA, ²Yale University School of Medicine; West Haven VA, New Haven, CT, ³Yale School of Medicine; West Haven VA; Berkshire Medical Center, Lenox, MA, ⁴Yale University School of Medicine; Yale School of Public Health; West Haven VA, West Haven, CT
Background/Purpose: Rheumatoid arthritis (RA) is the most common chronic inflammatory arthritis, affecting 1-2% of the population. Estimates of the incidence of RA in patients with…
Abstract Number: 0196 • ACR Convergence 2020
Objectively-Measured Obstructive Sleep Apnea Is Frequent Among Individuals with Rheumatoid Arthritis
Stephanie Rush¹, Sarah Morsi², Jose Pinzón Tirado², Laura Trupin², Katie Stone³ and Patricia Katz⁴, ¹University of California, San Francisco, San Francisco, CA, ²UCSF, San Francisco, CA, ³California Pacific Medical Center Research Institute, San Francisco, CA, ⁴University of California, San Francisco, Novato, CA
Background/Purpose: Despite frequent reports of sleep problems, accurate information on sleep disturbance in rheumatoid arthritis (RA) is not available. Studies using objective measures of sleep…
Abstract Number: 0197 • ACR Convergence 2020
The Clinical and Laboratory Features of Seronegative Rheumatoid Arthritis with and Without Malignancy
Misako Higashida-Konishi¹, Keisuke Izumi², Satoshi Hama², Hiroshi Takei², Yutaka Okano³ and Hisaji Ohshima², ¹Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Meguro-ku, Tokyo, Japan, ²Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Tokyo, Japan, ³Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Kawasaki, Japan
Background/Purpose: Patients with elderly onset rheumatoid arthritis(RA) have been reported to be less positive for RF(rheumatoid factor) and ACPA(anti-cyclic citrullinated peptide antibody), and have a…
Abstract Number: 0198 • ACR Convergence 2020
A Prospective Cohort Study of Vehicle Control as a Measure of Driving Performance in Patients with Rheumatoid Arthritis
Kaleb Michaud¹, Jennifer Merickel¹, Yeongjin Gwon¹, Harlan Sayles¹, Haley Kampschnieder¹, Rebecca Hiebert¹, Alison Petro¹, Bryant England¹, Matthew Rizzo¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Automobile driving is an instrumental activity of daily living. Owing to symptoms and functional impairment, patients with rheumatoid arthritis (RA) rely disproportionately on driving…
Abstract Number: 0199 • ACR Convergence 2020
A Phase 1, Randomized, Open-label, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of the Auto-injector and Pre-filled Syringe of CT-P17, a Proposed, Higher Concentration Biosimilar (100 mg/mL) Adalimumab, in Healthy Subjects
Edward C Keystone¹, Daniel Furst*², Jonathan Kay³, EunJin Choi⁴, Antonia Davidson⁵, YunJu Bae⁴, Darin Brimhall⁶, SangJoon Lee⁴, SungHyun Kim⁴ and DaHye Kwak⁴, ¹Mount Sinai Hospital, Toronto, ON, Canada, ²Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, ³University of Massachusetts Medical School, Worcester, MA, ⁴Celltrion, Inc., Incheon, Republic of Korea, ⁵PPD Development, Austin, TX, ⁶PPD Development, Las Vegas, NV
Background/Purpose: CT-P17 is a recombinant human monoclonal antibody that was developed as the first biosimilar adalimumab with high concentration (100 mg/mL) and citrate-free formulation. The…
Abstract Number: 0200 • ACR Convergence 2020
Predictors of Durable Clinical Response to Tofacitinib 11 Mg Once Daily with or Without Methotrexate in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Data from a Phase 3b/4 Methotrexate Withdrawal Study
Kunihiro Yamaoka¹, Stanley B Cohen², Naonobu Sugiyama³, Harry Shi⁴, Jose L Rivas⁵, Annette Diehl⁴ and Josef Smolen⁶, ¹Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan, ²Metroplex Clinical Research Center, Dallas, TX, ³Pfizer Japan Inc, Tokyo, Japan, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer SLU, Madrid, Spain, ⁶Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: ORAL Shift, a global Phase 3b/4 non-inferiority study, demonstrated sustained efficacy/safety of tofacitinib modified-release (MR) 11 mg QD following MTX withdrawal in patients (pts)…
Abstract Number: 0201 • ACR Convergence 2020
A Multicenter, Randomized, Placebo-controlled, Double-blind Phase 2 Study of SHR0302 versus Placebo in Chinese Subjects with Moderate to Severe Active Rheumatoid Arthritis (RA)
Xiaofeng Zeng¹, Ying Jiang², Ying Yang³ and Hanying Li⁴, ¹Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China (People's Republic), ²Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China (People's Republic), ³Jiangsu Hengrui Medicine Co., Ltd, Guangzhou, China (People's Republic), ⁴Jiangsu Hengrui Medicine Co., Ltd, Shanghai, China (People's Republic)
Background/Purpose: Proinflammatory cytokine activation of JAK/STAT signal pathway is critical in the pathogenesis and progression of RA. SHR0302, a potent and selective inhibitor of JAK1,…
Abstract Number: 0202 • ACR Convergence 2020
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 8.4 Years: An Updated Integrated Safety Analysis
Kevin Winthrop¹, Tsutomu Takeuchi², Gerd Burmester³, Patrick Durez⁴, Walter Deberdt⁵, Douglas Schlichting⁶, Scott Beattie⁶, Daojun Mo⁷, Chad Walls⁶ and Josef Smolen⁸, ¹Oregon Health & Science University, Portland, OR, ²Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan, ³Charité University Hospital Berlin, Berlin, Germany, ⁴Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, ⁵Eli Lilly and Company, Brussels, Belgium, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly and Company, Carmel, IN, ⁸Medical University of Vienna, Vienna, Austria
Background/Purpose: Baricitinib (bari) is an oral selective Janus kinase (JAK)1/JAK 2 inhibitor approved for the treatment of moderately to severely active rheumatoid arthritis (RA) in…
Abstract Number: 0203 • ACR Convergence 2020
Safety of Baricitinib in Patients with Rheumatoid Arthritis: Interim Report from All-Case Post‑Marketing Study in Clinical Use
Tatsuya Atsumi¹, Nami Okamoto², Nobunori Takahashi³, Naoto Tamura⁴, Atsuo Nakajima⁵, Ayako Nakajima⁶, Takao Fujii⁷, Hiroaki Matsuno⁸, Yuko Takahashi⁹, Fumie Inui⁹, Naoto Tsujimoto⁹, Atsushi Nishikawa⁹, Taeko Ishii⁹, Tsutomu Takeuchi¹⁰, Masataka Kuwana¹¹ and Michiaki Takagi¹², ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan, ²Department of Rheumatology and Allergy of Pediatrics, Osaka Medical College, Takatsuki, Osaka, Japan, ³Department of Orthopaedics/Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan, ⁴Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Bunkyō, Tokyo, Japan, ⁵Ueno Touseki Clinic, Kitasaku District, Nagano, Japan, ⁶Center for Rheumatic Diseases, Mie University Hospital, Tsu, Mie, Japan, ⁷Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Wakayama, Japan, ⁸Matsuno Clinic for Rheumatic Diseases, Toyama, Toyama, Japan, ⁹Eli Lilly, Kobe, Hyogo, Japan, ¹⁰Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan, ¹¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Tokyo, Japan, ¹²Department of Orthopaedic Surgery, Yamagata University Faculty of Medicine, Yamagata, Yamagata, Japan
Background/Purpose: To evaluate the safety of baricitinib in rheumatoid arthritis (RA) patients in clinical use.Methods: An all-case post-marketing study of baricitinib, started in September 2017,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].